Since SARS-CoV-2 outbreak in December 2019, world health-system has been severely
impacted with increased hospitalization, Intensive-Care-Unit (ICU) access and high mortality …

To the Editor, The updated post-marketing analysis by Peng et al.[1], who queried the FDA
Adverse Event Reporting System (FAERS) from the first quarter of 2018 to the first quarter of …

The Janus kinase (JAK) family enzymes are non-receptor tyrosine kinases that
phosphorylate cytokine receptors and signal transducer and activator of transcription (STAT) …

Background There are conflicting reports on the results of several of the latest clinical trials
related to the use of baricitinib in the management of COVID-19 patients. The aim of the …

The Janus kinase (JAK) family of nonreceptor protein-tyrosine kinases consists of JAK1,
JAK2, JAK3, and TYK2 (Tyrosine Kinase 2). Each of these proteins contains a JAK …

Autoimmune and inflammatory diseases are common and diverse, and they can affect
nearly any organ system. Much of the pathogenesis of these diseases is related to …

Background Due to the high incidence and mortality of the worldwide COVID-19 pandemic,
beneficial effects of effective antiviral and anti-inflammatory drugs used in other diseases …

Background and objective The most important presentation of COVID-19 is hyper
inflammatory condition and cytokine storm that occurs due to excessive increase of the …

Baricitinib is known to reduce mortality and disease progression in COVID‐19 patients;
however, the data are inconsistent. Therefore, it needs to be explored to further understand …

Most persons who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) are asymptomatic or have only mild-to-moderate symptoms, whereas others have …